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Objective: PI susceptibility results from a complex interplay between protease and Gag proteins, with Gag show-
ing wide variation across HIV-1 subtypes. We explored the impact of pre-treatment susceptibility on the outcome
of lopinavir/ritonavir monotherapy.
Methods: Treatment-naive individuals who experienced lopinavir/ritonavir monotherapy failure from the
MONARK study were matched (by subtype, viral load and baseline CD4 count) with those who achieved virological
response (‘successes’). Successes were defined by viral load ,400 copies/mL after week 24 and ,50 copies/mL
from week 48 to week 96. Full-length Gag–protease was amplified from patient samples for in vitro phenotypic
susceptibility testing, with susceptibility expressed as fold change (FC) relative to a subtype B reference strain.
Results: Baseline lopinavir susceptibility was lower in viral failures compared with viral successes, but the
differences were not statistically significant (median lopinavir susceptibility: 4.4 versus 8.5, respectively,
P¼0.17). Among CRF02_AG/G patients, there was a significant difference in lopinavir susceptibility between
the two groups (7.1 versus 10.4, P¼0.047), while in subtype B the difference was not significant (2.7 versus
3.4, P¼0.13). Subtype CRF02_AG/G viruses had a median lopinavir FC of 8.7 compared with 3.1 for subtype B
(P¼0.001).
Conclusions: We report an association between reduced PI susceptibility (using full-length Gag–protease
sequences) at baseline and subsequent virological failure on lopinavir/ritonavir monotherapy in antiretroviral-
naive patients harbouring subtype CRF02_AG/G viruses. We speculate that this may be important in the context
of suboptimal adherence in determining viral failure.
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Introduction
Efficacious, long-term HAART treatment entails both a high finan-
cial cost and a risk of significant side effects, and exploration of
alternative treatment regimens is necessary. Simplification strat-
egies have been investigated to reduce the number of antiretro-
viral drugs required as part of treatment regimens without
compromising treatment efficacy. Boosted PI (bPI) monotherapy
has been studied in a small number of randomized trials, with
poorer outcomes compared with standard triple therapy when
used as initial therapy in the MONARK study1,2 or as second-line
therapy after an NNRTI first-line failure in resource-limited set-
tings.3,4 When used as a maintenance regimen in patients with
a substantial period of viral suppression, bPI monotherapy may
be considered as a treatment option to reduce exposure to anti-
retrovirals and NRTI-associated toxicities with the possibility of
re-intensification when needed.5 – 8
Based on an estimated 10 million HIV-1-infected patients on
antiretroviral therapy9 and a virological failure rate of 20%,10 around
2 million patients worldwide qualify for PI-based second-line
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treatment, most likely lopinavir boosted with ritonavir. Widespread
use of this class of drug raises some concerns, given our poor under-
standing of virological failure. Indeed, the majority of patients
experiencing failure of first-line combined ART with ritonavir-
boosted PIs do so without evidence of major PI-associated drug
resistance by standard methods.11,12 Studies have provided evi-
dence for the role of Gag in PI susceptibility13 – 15 and have been
reviewed.16 In addition, the inclusion of full-length patient-derived
Gag alongside its co-evolved protease in in vitro phenotypic assays
has been shown to affect PI susceptibility in both treatment-naive
and treatment-experienced patients.17– 19 More recently, Env has
been implicated in drug resistance following PI exposure.20
MONARK investigated lopinavir/ritonavir monotherapy in com-
parison with lopinavir/ritonavir plus two NRTIs at treatment initi-
ation in treatment-naive patients, with the monotherapy arm
showing higher rates of virological failure.1,2 HIV-1 subtypes B
and CRF02_AG were the dominant subtypes, and a higher failure
rate was observed in the latter.21,22 This subtype is prevalent in
West Africa and is also present in migrant HIV-1-infected popula-
tions in Europe, where subtype B otherwise dominates. Given the
evidence for the importance of the inclusion of full-length Gag
alongside its co-evolved protease in phenotypic assays and our
previous study demonstrating reduced phenotypic susceptibility
in patients experiencing virological failure in the MONARK trial,
we hypothesized that Gag–protease-mediated susceptibility
would differ between patients failing therapy and those with
viral suppression, as well as between divergent strains (sub-
types).23 This study sought to investigate the viral determinants
of treatment failure in the MONARK lopinavir/ritonavir monother-
apy arm trial by studying co-evolved, full-length Gag–protease
from patients achieving virological response and experiencing
virological failure in phenotypic PI susceptibility assays.
Methods
Study participants
Based on sample availability from MONARK, we studied eight individuals
with lopinavir/ritonavir monotherapy failure (Figure S1, available as
Supplementary data at JAC Online) and to these we matched eight
patients (by subtype, viral load and baseline CD4 count) who achieved
virological response (‘successes’). Successes were defined by viral load
,400 copies/mL after week 24 and ,50 copies/mL from week 48 to
week 96 (Table 1).
Amplification of full-length Gag–protease
Full-length Gag–protease was amplified from patient samples as previ-
ously described.24 Clonal sequencing of up to 10 viral variants for each
sample was performed. The variant that most closely represented the con-
sensus was taken forward for phenotypic testing. Protease sequences
were analysed for PI resistance mutations using the Stanford Resistance
Database (http://hivdb.stanford.edu/) (Table S1).25
PI susceptibility and infectivity assays
PI susceptibility and infectivity were determined using previously described
single-cycle assays.17,19,24 Briefly, 293 T cells were co-transfected with
p8.9NSX+-derived test vector containing patient gag–protease, pMDG
expressing vesicular stomatitis virus envelope glycoprotein (VSV-g) and
pCSFLW expressing the firefly luciferase reporter gene with HIV-1 packaging
signal. To determine PI susceptibility, transfected cells were seeded with ser-
ial dilutions of lopinavir and harvested pseudovirions used to infect fresh
293 T cells. To determine strain infectivity, transfected cells were seeded
in the absence of drug. Infectivity was monitored by measuring luciferase
activity 48 h after infection. All experiments were performed in duplicate.
Statistical analysis
We compared baseline characteristics of viral failures and successes using
the Mann–Whitney rank sum test for continuous variables and Fisher’s
exact test for categorical variables. For analyses of lopinavir susceptibility,
we defined each individual’s susceptibility as the geometric mean of the
two measurements. We compared lopinavir susceptibility between viral
failures and successes by the Mann–Whitney rank sum test, which is
robust for data that are not normally distributed. To check the sensitivity
of our results to the choice of analytical method, we repeated the analyses
using conditional logistic regression on the matched participants using
viral failure or success as the outcome variable and log lopinavir fold
change (FC) as the exposure. These sensitivity analyses gave concordant
results.
Results
Analyses involved 16 participants, of whom 8 were cases (failures)
and 8 were controls (successes). Ten participants harboured HIV
subtype CRF02_AG or G and six harboured subtype B, with sub-
types split evenly between cases and controls. No patient har-
boured virus with major or minor resistance mutations to
lopinavir, although a number of polymorphisms were present in
protease, some of which are considered consensus amino acid
positions in subtype CRF02_AG and G viruses (Table S1). Baseline
CD4 and viral load were marginally higher in cases, but these dif-
ferences were not statistically significant (Table 1).
Baseline lopinavir susceptibility was lower in viral failures than
viral successes, but the differences were not statistically signifi-
cant [median (IQR) lopinavir susceptibility in virological successes
versus failures: 4.4 (2.9– 7.7) versus 8.5 (3.6 –11), P¼0.17,
Figure 1]. When considering only the 10 CRF02_AG/G patients,
Table 1. Characteristics of study participants and virus isolates from participants
Baseline characteristics Failures (n¼8) Successes (n¼8) P value for difference between groups
Sex, n (% male) 8 (100) 7 (87.5) 1
Subtype B, n (%) 3 (37.5) 3 (37.5) 1
VL (copies/mL), median (IQR) 53200 (41200–79850) 38650 (27300–59000) 0.23
CD4 (cells/mm3), median (IQR) 256.5 (211–297) 243 (223–336) 0.10
Viral infectivity, median (IQR) 78 (60–101) 96 (79–99) 0.29
VL, viral load.
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there was a significant difference in lopinavir susceptibility
between the two groups [median (IQR) lopinavir susceptibility in
virological successes versus failures: 7.1 (4.7–8.4) versus 10.4
(8.9–11.5), P¼0.047, Figure 1]. When considering only subtype
B patients (n¼6), lopinavir susceptibility appeared lower in viro-
logical failures than successes, while the difference was not sig-
nificant (median lopinavir susceptibility in virological successes
versus failures: 2.7 versus 3.4, P¼0.13) (Figure 1).
These data suggest there may be an inherent difference in sus-
ceptibility between subtypes AG/G and B. Subtype CRF02_AG /G
viruses had a median (IQR) lopinavir FC of 8.7 (7.1 –10.4),
compared with 3.1 (2.7–3.4) for subtype B (P¼0.001) (Figure 2).
This difference in lopinavir susceptibility between viruses was con-
sistent when observed within virological successes (P¼0.025) or
failures (P¼0.025).
Finally, we also examined the relationship between drug sus-
ceptibility and replication of the viruses from each patient.
Lopinavir FC showed a weak negative association with in vitro rep-
lication capacity (r¼20.15) (Figure 3a), and was not associated
with plasma viral load (Figure 3b). Replication capacity (over a sin-
gle round of infection in vitro) was not significantly associated
with virological failure, with marginally lower levels in virological
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Figure 1. Box plots of phenotypic assay FC in EC50 of lopinavir (LPV) by treatment outcome.
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Figure 2. Box plots of phenotypic assay FC in EC50 of lopinavir (LPV) by subtype.
HIV-1 subtype, treatment failure and PI susceptibility
245
JAC
failures compared with successes [median (IQR) in virological suc-
cesses versus failures: 96 (79–99) versus 78 (60–101), P¼0.29].
Discussion
A previous analysis of the MONARK study suggested an associ-
ation between the HIV-1 subtype AG (circulating in West Africa)
and poorer outcome of lopinavir/ritonavir monotherapy, although
there were confounding factors such as treatment adherence.22
The evaluation of a dual regimen of tenofovir plus lopinavir/
ritonavir as first line in West Africa in the DAYANA trial also showed
poor virological responses relative to standard NNRTI-based
regimens,26 while the non-inferiority of another dual regimen,
lopinavir/ritonavir plus lamivudine compared with a lopinavir/
ritonavir-based triple regimen was demonstrated in other settings
in the GARDEL trial.27 Here, we performed a case–control study
within MONARK to test the hypothesis that baseline susceptibility,
as determined by a full-length cognate Gag–protease assay, is
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Figure 3. Scatter plot of FC in EC50 of lopinavir (LPV) versus (a) replicative capacity and (b) baseline viral load.
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correlated with outcome. In the primary analysis, in which sub-
type B and CRF02_AG/G were analysed together, we found a non-
significant association between lopinavir susceptibility and failure
(P¼0.14). In a subtype CRF02_AG/G-specific analysis, we found a
significant difference between the two groups despite a relatively
small sample size. Furthermore, subtype CRF02_AG/G viruses are
substantially less susceptible to lopinavir than subtype B and this
may have contributed to the findings of the MONARK investigators
that subtype CRF02_AG patients were more likely to experience
virological failure than those harbouring subtype B.
To date, phenotypic analysis using the commercial Phenosense
assay (using a patient-derived protease with a subtype-mismatched
Gag) had been performed on viruses derived from patients experi-
encing virological failure in the lopinavir/ritonavir monotherapy
arm with the appearance of major PI resistance mutations.28
This analysis showed that in three patients with subtype
CRF02_AG virus the pre-therapy EC50 FC was 0.57, 0.59 and
0.87 relative to the subtype B reference strain. In two subtype
B-infected individuals, FCs of 1.46 and 1.49 were reported
pre-therapy. The Phenosense assay result would suggest that
subtype CRF02_AG viruses in MONARK are more susceptible
than subtype B, in direct contradiction to our data using matched
Gag and protease sequences (Figure 2 and Gupta et al.17).
However, the reduced PI susceptibility present in the variants
from viral failure patients at baseline does not fully explain the
subsequent treatment failure experienced. Six of the eight failure
patients did initially achieve virological suppression,400 copies/mL
on lopinavir/ritonavir monotherapy at week 24, before experien-
cing virological failure after .40 weeks of the trial. We hypothe-
size that PI monotherapy is potent enough to suppress viral
replication with high adherence initially, but that reduced PI sus-
ceptibility lowers the tolerance or ‘buffer zone’ for subsequent
suboptimal adherence. It is possible that patients with viruses
demonstrating reduced PI susceptibility at baseline may be better
suited to standard combined ART, which is likely to be more forgiv-
ing of reduced adherence, as three active agents are present.
Alternatively, identification of these patients before treatment
initiation would enable interventions to increase adherence and
reduce this risk of failure. A third possibility is to closely monitor
patients on PI monotherapy and intensify if low-level viraemia
or viral rebound occurs.8,29
Limitations of our study include the relatively small sample
size, the inclusion of more subtype CRF02_AG viruses in compari-
son with B and the possibility of viral recombination through our
PCR and cloning strategy. Finally, our assay system did not incorp-
orate the native gp160 envelope.20
In conclusion, we report an association between reduced PI
susceptibility at baseline in the absence of known resistance
mutations and subsequent virological failure on lopinavir/ritonavir
monotherapy in patients harbouring subtype CRF02_AG/G viruses.
This is an important finding as it indicates that it may be possible
to predict treatment outcome on lopinavir/ritonavir monotherapy
from baseline PI susceptibility. We hypothesize that reduced base-
line PI susceptibility renders patients more vulnerable to viro-
logical rebound when their adherence is sub-optimal. This study
suggests that lopinavir/ritonavir monotherapy should not be
used in antiretroviral-naive patients infected with CRF02_AG. In
maintenance therapy, studies are still needed to evaluate the
impact of HIV-1 subtypes on virological response to PI/ritonavir
monotherapy, as this regimen may be considered as a treatment
option for individual patients in whom real-time viral load moni-
toring is available.
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